Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2008

View Archived Issues

Novel microtubule-stabilizing drug improves neurofibrillary Tau pathology in vitro and in vivo

Novel NMDA receptor modulator shows neuroprotection against ethanol withdrawal, consumption

Novel therapeutic agents for cardiovascular disorders imparted in recent patent literature

Sanofi-aventis reports preclinical data of novel trioxaquine candidate for malaria

Long-term retreatment of HBV patients with entecavir effective

Multiple doses of MK-7009 safe in HCV patients

Oncolytics Biotech presents clinical results with its novel oncolytic reovirus type 3 Dearing

New neuropsychiatric agents reported

Recent Daiichi Sankyo patent discloses novel antithrombotic agents

EMEA recommends the suspension of the marketing authorization of Ionsys

Moberg reports results from phase III clinical study of K-101 for nail fungus

Resolvyx to initiate phase I/II clinical trial of RX-10045 in moderate to severe dry eye

European Commission withdraws Schering-Plough's marketing authorization for Viraferon

Lilly completes cash tender offer for ImClone Systems

Aeolus initiates animal study of AEOL-10150 in damage to the lungs due to radiation

CHMP recommends approval of Enbrel for severe plaque psoriasis in pediatric patients

Genentech and Roche report results from RIBBON 1 phase III clinical study of Avastin

FDA grants pralatrexate orphan drug status for diffuse large B-cell lymphoma

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

CHMP issues positive opinion for Stelara in plaque psoriasis

Essentialis completes patient enrollment in phase II DCCR trial

Factor IXFc receives FDA orphan drug status for hemophilia B

FDA accepts DX-88 filing and grants priority review for hereditary angioedema

Valdoxan receives CHMP positive opinion for major depressive disorder

Xenazine tablets available in U.S. for chorea associated with HD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...